pegfr Search Results


92
Revvity egfr py1068 antibodies antibodies alphalisa surefire p egf receptor
Egfr Py1068 Antibodies Antibodies Alphalisa Surefire P Egf Receptor, supplied by Revvity, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfr py1068 antibodies antibodies alphalisa surefire p egf receptor/product/Revvity
Average 92 stars, based on 1 article reviews
egfr py1068 antibodies antibodies alphalisa surefire p egf receptor - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

91
Addgene inc pegfr patagrfp
Pegfr Patagrfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pegfr patagrfp/product/Addgene inc
Average 91 stars, based on 1 article reviews
pegfr patagrfp - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

88
fluidigm anti phospho egfr 146nd
Anti Phospho Egfr 146nd, supplied by fluidigm, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho egfr 146nd/product/fluidigm
Average 88 stars, based on 1 article reviews
anti phospho egfr 146nd - by Bioz Stars, 2026-03
88/100 stars
  Buy from Supplier

90
Merck KGaA polyclonal rabbit anti-pegfr antibody
Polyclonal Rabbit Anti Pegfr Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal rabbit anti-pegfr antibody/product/Merck KGaA
Average 90 stars, based on 1 article reviews
polyclonal rabbit anti-pegfr antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Promega pegfr 3=-utr reporter
Pegfr 3= Utr Reporter, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pegfr 3=-utr reporter/product/Promega
Average 90 stars, based on 1 article reviews
pegfr 3=-utr reporter - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Becton Dickinson the antibodies against egfr and pegfr
The Antibodies Against Egfr And Pegfr, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/the antibodies against egfr and pegfr/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
the antibodies against egfr and pegfr - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
GeneTex anti-egfr gtx132810
Anti Egfr Gtx132810, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-egfr gtx132810/product/GeneTex
Average 90 stars, based on 1 article reviews
anti-egfr gtx132810 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Cytocell Inc anti pegfr y1086 ab
A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR <t>Y1086</t> and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.
Anti Pegfr Y1086 Ab, supplied by Cytocell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pegfr y1086 ab/product/Cytocell Inc
Average 90 stars, based on 1 article reviews
anti pegfr y1086 ab - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Upstate Biotechnology Inc mouse anti-pegfr antibody
A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR <t>Y1086</t> and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.
Mouse Anti Pegfr Antibody, supplied by Upstate Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-pegfr antibody/product/Upstate Biotechnology Inc
Average 90 stars, based on 1 article reviews
mouse anti-pegfr antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Biocare Medical primary monoclonal mouse anti-human antibodies pegfr
A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR <t>Y1086</t> and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.
Primary Monoclonal Mouse Anti Human Antibodies Pegfr, supplied by Biocare Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary monoclonal mouse anti-human antibodies pegfr/product/Biocare Medical
Average 90 stars, based on 1 article reviews
primary monoclonal mouse anti-human antibodies pegfr - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
WuXi AppTec pegfr-y1125
A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR <t>Y1086</t> and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.
Pegfr Y1125, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pegfr-y1125/product/WuXi AppTec
Average 90 stars, based on 1 article reviews
pegfr-y1125 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Abnova antibody rabbit polyclonal anti-pegfr-thr654
Fourteen EGFR tyrosine, serine and threonine phosphorylation sites were screened via in situ PLA and immunoblotting analyses.
Antibody Rabbit Polyclonal Anti Pegfr Thr654, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody rabbit polyclonal anti-pegfr-thr654/product/Abnova
Average 90 stars, based on 1 article reviews
antibody rabbit polyclonal anti-pegfr-thr654 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.

Journal: Oncotarget

Article Title: Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “ in vitro ” and correlating with progression “ in vivo ”

doi: 10.18632/oncotarget.12404

Figure Lengend Snippet: A. Flow cytometry of HUTS-21 expression in LNCaP cells left untreated (empty histogram), treated with D2B+gam (black histogram) or treated with D2B+gam in the presence of PP1 (grey histogram). Isotype control is depicted. B. Representative immunoblotting of EGFR-IP of LNCaP cells left untreated (ctr) or subjected to gam- or D2B+gam cross-linking. PSMA pulled out band is indicated. Equal amounts of cell lysate were immunoprecipitated C. Immunoblotting of crude lysates of LNCaP cells treated as in B and probed with anti HUTS-21, anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. D. Immunoblotting of LNCaP cells treated as in B in the presence or absence of PP1 or SU665 at the indicated doses. E. Immunoblotting of LNCaP wt cells, FLNa or beta 1 silenced LNCap cells as in B and probed with anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Results are representative of at least two experiments. Equal amounts of cell lysates were used for EGFR IP . Arrows indicate relevant bands in all panels.

Article Snippet: Only the anti pEGFR Y1086 Ab showed diffuse immunoexpression on Cytocell inclusion and therefore used on TMA [ ].

Techniques: Flow Cytometry, Expressing, Control, Western Blot, Immunoprecipitation

A. Beta 1 and PSMA expression in NNA and PCa tissue lysates. Beta1 B. or PSMA C. IP prepared from NNA and PCa tissue lysates. Co-immunoprecipitated proteins are detected by immunoblotting as indicated D. Immunoblotting of NNA and PCa tissue lysates probed with anti EGFR, anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Actin shows loading in A and D.

Journal: Oncotarget

Article Title: Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “ in vitro ” and correlating with progression “ in vivo ”

doi: 10.18632/oncotarget.12404

Figure Lengend Snippet: A. Beta 1 and PSMA expression in NNA and PCa tissue lysates. Beta1 B. or PSMA C. IP prepared from NNA and PCa tissue lysates. Co-immunoprecipitated proteins are detected by immunoblotting as indicated D. Immunoblotting of NNA and PCa tissue lysates probed with anti EGFR, anti pEGFR Y1086 and anti pEGFR Y1173 mAbs. Actin shows loading in A and D.

Article Snippet: Only the anti pEGFR Y1086 Ab showed diffuse immunoexpression on Cytocell inclusion and therefore used on TMA [ ].

Techniques: Expressing, Immunoprecipitation, Western Blot

A. Representative immunohistochemistry of TMA showing high score (2+) for p130CAS (a, b) and pEGFR Y1086 (c, d). Magnification is as follows: 4X (a, c), 20X (b, d). p130CAS high score: ≥30% of the cells stained strongly, low score: ≥10% of the cells stained weakly or <30% stained strongly. pEGFR Y1086 high score: ≥10% of cells stained strongly, low score: >10% of the cells stained weakly B, C. Results of TAM immunohistochemistry for p130CAS (B) (16 patients) and pEGFR Y1086 (C) (10 out of 16 patients) with castration resistant prostate adenocarcinoma. In uppercase H and L indicate high and low score respectively, “a” indicates samples positive for both p130CAS and pEGFR Y1086 , “ne” indicates neuroendocrine. p130CAS expression was scored as 2+), or as 1+) or as 0 (negative). pEGFR Y1086 expression was scored as 2+), or as 1+).

Journal: Oncotarget

Article Title: Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “ in vitro ” and correlating with progression “ in vivo ”

doi: 10.18632/oncotarget.12404

Figure Lengend Snippet: A. Representative immunohistochemistry of TMA showing high score (2+) for p130CAS (a, b) and pEGFR Y1086 (c, d). Magnification is as follows: 4X (a, c), 20X (b, d). p130CAS high score: ≥30% of the cells stained strongly, low score: ≥10% of the cells stained weakly or <30% stained strongly. pEGFR Y1086 high score: ≥10% of cells stained strongly, low score: >10% of the cells stained weakly B, C. Results of TAM immunohistochemistry for p130CAS (B) (16 patients) and pEGFR Y1086 (C) (10 out of 16 patients) with castration resistant prostate adenocarcinoma. In uppercase H and L indicate high and low score respectively, “a” indicates samples positive for both p130CAS and pEGFR Y1086 , “ne” indicates neuroendocrine. p130CAS expression was scored as 2+), or as 1+) or as 0 (negative). pEGFR Y1086 expression was scored as 2+), or as 1+).

Article Snippet: Only the anti pEGFR Y1086 Ab showed diffuse immunoexpression on Cytocell inclusion and therefore used on TMA [ ].

Techniques: Immunohistochemistry, Staining, Expressing

Fourteen EGFR tyrosine, serine and threonine phosphorylation sites were screened via in situ PLA and immunoblotting analyses.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: Fourteen EGFR tyrosine, serine and threonine phosphorylation sites were screened via in situ PLA and immunoblotting analyses.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Phospho-proteomics, In Situ, Western Blot

H1299 cells stably expressed the empty vector, EGFR-WT or mutant EGFR-L858R. (A) After stimulation with EGF (10 ng/ml) in serum-free medium for 10 minutes, cell extracts were subjected to immunoblotting analysis with the indicated phospho-tyrosine antibodies. EGF-dependent (EGFR-Tyr992, -Tyr1148 and -Tyr1068) and EGF-independent [EGFR-Tyr845, -Tyr974, -Tyr1086 and -Tyr1101, -Thr654 (see below) and -Ser1046 (see below)] phosphorylation were observed in H1299 cells expressing EGFR-L858R mutant. The phosphorylation of EGFR-Thr654 (B) and -Ser1046 (C) with or without EGF treatment in different lung cancer cell lines was monitored via in situ PLA. The quantification of in situ PLA is shown on the right. EGFR-Thr654 and -Ser1046 were phosphorylated upon EGF treatment in H1299-EGFR-WT cells, whereas their phosphorylation was EGF-independent in H1299-EGFR-L858R cells. (D) Immunoblotting analysis of EGFR-Thr654 and -Ser1046 was performed in EGFR mutant cells (H1975, which contains the EGFR-L858R and -T790M mutants) and cells expressing EGFR-WT (A549). The phosphorylation of EGFR-Tyr1068 was induced by EGF. The phosphorylation of EGFR-Thr654 and -Ser1046 was EGF-independent in H1975 and H1299-EGFR-L858R cells as determined by immunoblotting.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: H1299 cells stably expressed the empty vector, EGFR-WT or mutant EGFR-L858R. (A) After stimulation with EGF (10 ng/ml) in serum-free medium for 10 minutes, cell extracts were subjected to immunoblotting analysis with the indicated phospho-tyrosine antibodies. EGF-dependent (EGFR-Tyr992, -Tyr1148 and -Tyr1068) and EGF-independent [EGFR-Tyr845, -Tyr974, -Tyr1086 and -Tyr1101, -Thr654 (see below) and -Ser1046 (see below)] phosphorylation were observed in H1299 cells expressing EGFR-L858R mutant. The phosphorylation of EGFR-Thr654 (B) and -Ser1046 (C) with or without EGF treatment in different lung cancer cell lines was monitored via in situ PLA. The quantification of in situ PLA is shown on the right. EGFR-Thr654 and -Ser1046 were phosphorylated upon EGF treatment in H1299-EGFR-WT cells, whereas their phosphorylation was EGF-independent in H1299-EGFR-L858R cells. (D) Immunoblotting analysis of EGFR-Thr654 and -Ser1046 was performed in EGFR mutant cells (H1975, which contains the EGFR-L858R and -T790M mutants) and cells expressing EGFR-WT (A549). The phosphorylation of EGFR-Tyr1068 was induced by EGF. The phosphorylation of EGFR-Thr654 and -Ser1046 was EGF-independent in H1975 and H1299-EGFR-L858R cells as determined by immunoblotting.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Stable Transfection, Plasmid Preparation, Mutagenesis, Western Blot, Phospho-proteomics, Expressing, In Situ

(A) We used ProtoArray™ to identify EGFR as a novel interaction partner for AURKA. Briefly, expressed, recombinant his-tagged human AURKA was probed on ProtoArray™ human protein microarrays at seven concentrations (0, 0.5, 1.0, 5.0, 10, 50 and 100 ng/µl) in duplicate. It should be noted that EGFR-L861Q, but not EGFR-WT, was initially identified to interact with AURKA. (B) HEK293T were co-transfected with Myc-EGFR (EGFR-WT, EGFR-L858R and -L861Q mutants) and Flag-AURKA [AURKA-WT and AURKA-kinase dead (KD)]. After transfection for 48 hours, the cell extracts were subjected to co-immunoprecipitation with an anti-FLAG M2 affinity gel. Protein expression was determined by immunoblotting with anti-Myc and anti-FLAG antibodies. It showed that both EGFR-WT and mutated EGFR associates with AURKA-WT and AURKA-KD. Similar results were observed in at least three independent experiments. (C) The EGFR-AURKA interaction with or without EGF stimulation (10 ng/ml for 10 minutes) was determined via in situ PLA in A549 (EGFR-WT) and H1975 (EGFR-L858R-T790M mutations). Both EGFR-WT and -L858R mutant were associated with AURKA under EGF stimulation. The quantification of in situ PLA signals was shown on the right. (D) The phosphorylation sites of EGFR-Thr654 and -Ser1046 matched the substrate consensus sequences for AURKA. (E) H1975 cells showed more obvious phosphorylation at EGFR-Thr654, EGFR-Ser1046 and AURKA-Thr288 in nocodazole-arrested M-phase than in interphase.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: (A) We used ProtoArray™ to identify EGFR as a novel interaction partner for AURKA. Briefly, expressed, recombinant his-tagged human AURKA was probed on ProtoArray™ human protein microarrays at seven concentrations (0, 0.5, 1.0, 5.0, 10, 50 and 100 ng/µl) in duplicate. It should be noted that EGFR-L861Q, but not EGFR-WT, was initially identified to interact with AURKA. (B) HEK293T were co-transfected with Myc-EGFR (EGFR-WT, EGFR-L858R and -L861Q mutants) and Flag-AURKA [AURKA-WT and AURKA-kinase dead (KD)]. After transfection for 48 hours, the cell extracts were subjected to co-immunoprecipitation with an anti-FLAG M2 affinity gel. Protein expression was determined by immunoblotting with anti-Myc and anti-FLAG antibodies. It showed that both EGFR-WT and mutated EGFR associates with AURKA-WT and AURKA-KD. Similar results were observed in at least three independent experiments. (C) The EGFR-AURKA interaction with or without EGF stimulation (10 ng/ml for 10 minutes) was determined via in situ PLA in A549 (EGFR-WT) and H1975 (EGFR-L858R-T790M mutations). Both EGFR-WT and -L858R mutant were associated with AURKA under EGF stimulation. The quantification of in situ PLA signals was shown on the right. (D) The phosphorylation sites of EGFR-Thr654 and -Ser1046 matched the substrate consensus sequences for AURKA. (E) H1975 cells showed more obvious phosphorylation at EGFR-Thr654, EGFR-Ser1046 and AURKA-Thr288 in nocodazole-arrested M-phase than in interphase.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Recombinant, Transfection, Immunoprecipitation, Expressing, Western Blot, In Situ, Mutagenesis, Phospho-proteomics

(A) The phosphorylation of EGFR-Tyr1068 was faster than that of EGFR-Thr654 and EGFR-Ser1046 under the EGF (10 ng/ml) stimulation. (B) The cells were serum-starved in the presence of VE-465 (1 nM or 100 nM), which is an AURKA inhibitor, for 16 hours and then treated with EGF (10 ng/ml) for 10 minutes. The phosphorylation of EGFR-Thr654 and EGFR-Ser1046, but not pEGFR-Tyr1068, was suppressed by VE-465. (C) The cells were serum-starved in the presence of Iressa (10 µM) for 16 hours and then treated with EGF (10 ng/ml) for 10 minutes. Iressa, which is an EGFR inhibitor, was used to monitor EGFR signaling in H1299 cells stably expressing EGFR-WT and EGFR-L858R mutant. The phosphorylation by AURKA at Thr288 was suppressed by Iressa in both cell lines. (D) H1975 cells were treated with VE-465 and/or Iressa (10 µM) for 16 hrs. VE-465 and Iressa can suppress pEGFR-Thr654 and -Ser1046 in H1975.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: (A) The phosphorylation of EGFR-Tyr1068 was faster than that of EGFR-Thr654 and EGFR-Ser1046 under the EGF (10 ng/ml) stimulation. (B) The cells were serum-starved in the presence of VE-465 (1 nM or 100 nM), which is an AURKA inhibitor, for 16 hours and then treated with EGF (10 ng/ml) for 10 minutes. The phosphorylation of EGFR-Thr654 and EGFR-Ser1046, but not pEGFR-Tyr1068, was suppressed by VE-465. (C) The cells were serum-starved in the presence of Iressa (10 µM) for 16 hours and then treated with EGF (10 ng/ml) for 10 minutes. Iressa, which is an EGFR inhibitor, was used to monitor EGFR signaling in H1299 cells stably expressing EGFR-WT and EGFR-L858R mutant. The phosphorylation by AURKA at Thr288 was suppressed by Iressa in both cell lines. (D) H1975 cells were treated with VE-465 and/or Iressa (10 µM) for 16 hrs. VE-465 and Iressa can suppress pEGFR-Thr654 and -Ser1046 in H1975.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Phospho-proteomics, Stable Transfection, Expressing, Mutagenesis

Each column indicates a patient and each row indicates an antibody. The IHC intensity in the patients was defined as 0, 1 and 2 for AURKA, pEGFR-Thr654 and pEGFR-Ser1046 staining.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: Each column indicates a patient and each row indicates an antibody. The IHC intensity in the patients was defined as 0, 1 and 2 for AURKA, pEGFR-Thr654 and pEGFR-Ser1046 staining.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Staining

Wilcoxon two-sample t-test for IHC staining in 25 NSCLC patients.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: Wilcoxon two-sample t-test for IHC staining in 25 NSCLC patients.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Immunohistochemistry

Spearman's non-parametric correlation test for IHC staining of 25 NSCLC patients.

Journal: PLoS ONE

Article Title: Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

doi: 10.1371/journal.pone.0055657

Figure Lengend Snippet: Spearman's non-parametric correlation test for IHC staining of 25 NSCLC patients.

Article Snippet: Heat-induced epitope retrieval was performed in an antigen retrieval solution at 100°C for 10 minutes with a microwave and the sections were then incubated with a rabbit polyclonal anti-pEGFR-Thr654 antibody (1∶300 dilution, Abnova), rabbit polyclonal anti-pEGFR-Ser1046 antibody (1∶100 dilution, Abnova), and rabbit polyclonal anti-AURKA antibody (1∶400 dilution, Sigma-Aldrich).

Techniques: Immunohistochemistry